Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Summary

DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.

Eligibility

Inclusion Criteria:

* Age over 18
* Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer
* Patient labeled on the primary lesion ER+HER2- (20)
* Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan
* Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan
* No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan.
* Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan
* Person affiliated to or benefiting from social security
* Person who has given written informed consent

Exclusion Criteria:

* Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor)
* Known allergy to 68Ga-DOTATOC or its excipients
* Subject refusing to sign the consent to participate
* Minor subject
* Subject excluded from another study
* Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP)
* Subject cannot be contacted in case of emergency

Conditions3

Browse More Trials